doi:10.16139/j.1007-9610.2019.01.005

[1] 王胤奎, 李子禹, 陕飞, 等. 我国早期胃癌的诊治现状——来自中国胃肠肿瘤外科联盟数据的启示[J]. 中华胃肠外科杂志,2018,21(2):168-174.
[2] Cunningham D, Allum WH, Stenning SP, et al.Periope-rative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
[3] Bang YJ, Kim YW, Yang HK, et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, rando-mized controlled trial[J]. Lancet,2012,379(9813):315-321.
[4] Sakuramoto S, Sasako M, Yamaguchi T, et al.Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med,2007,357(18):1810-1820.
[5] Schuhmacher C, Gretschel S, Lordick F, et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40 954[J]. J Clin Oncol,2010,28(35):5210-5218.
[6] Ychou M, Boige V, Pignon JP, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol,2011, 29(13):1715-1721.
[7] NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer[EB/OL]. Version 2.2018. (2018-05-22)[2018-12-03]. http://www.nccn.org.
[8] Edge SB, Byrd DR, Compton CC, et al.AJCC Cancer Staging Manual[M]. 7 ed. New York:Springer,2010.
[9] Amin MB, Edge SB, Greene FL, et al.AJCC Cancer Staging Manual[M]. 8 ed. New York:Springer,2017.
[10] Greene FL, Page DL, Fleming ID.AJCC Cancer Staging Manual[M]. 6 ed. New York:Springer,2002.
[11] Valentini V, Cellini F, Minsky BD, et al.Survival after radiotherapy in gastric cancer: systematic review and meta-analysis[J]. Radiother Oncol,2009,92(2):176-183.
[12] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084.
[13] Stahl M, Walz MK, Stuschke M, et al.Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856.
[14] Leong T, Smithers BM, Michael M, et al.TOPGEAR: a randomised phase Ⅲ trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)[J]. BMC Cancer,2015,15:532.
[15] Burmeister BH, Thomas JM, Burmeister EA, et al.Is concurrent radiation therapy required in patients recei-ving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial[J]. Eur J Cancer,2011,47(3):354-360.
[16] Persiani R, D'Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer(LAGC) treated with preoperative chemotherapy and D2-gastrectomy[J]. J Surg Oncol,2005,89(4):227-238.
[17] D'Ugo D, Persiani R, Rausei S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer[J]. Eur J Surg Oncol,2006,32(10):1105-1109.
[18] Spigel DR, Greco FA, Meluch AA, et al.Phase Ⅰ/Ⅱ trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in loca-lized carcinoma of the esophagus or gastroesophageal junction[J]. J Clin Oncol,2010,28(13):2213-2219.
[19] Ajani JA, Mansfield PF, Janjan N, et al.Multi-institu-tional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma[J]. J Clin Oncol,2004,22(14):2774-2780.
[20] Lowy AM, Feig BW, Janjan N, et al.A pilot study of preoperative chemoradiotherapy for resectable gastric cancer[J]. Ann Surg Oncol,2001,8(6):519-524.
[21] Ajani JA, Walsh G, Komaki R, et al.Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction[J]. Cancer,2004,100(11):2347-2354.
[22] Ajani JA, Mansfield PF, Crane CH, et al.Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome[J]. J Clin Oncol,2005,23(6):1237-1244.
[23] Ajani JA, Winter K, Okawara GS, et al.Phase Ⅱ trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response[J]. J Clin Oncol,2006,24(24):3953-3958.
[24] Wydmanski J, Suwinski R, Poltorak S, et al.The tole-rance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase Ⅱ study[J]. Radiother Oncol,2007,82(2):132-136.
[25] Reed VK, Krishnan S, Mansfield PF, et al.Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys,2008,71(3):741-747.
[26] Rivera F, Galan M, Tabernero J, et al.Phase Ⅱ trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma[J]. Int J Radiat Oncol Biol Phys,2009,75(5):1430-1436.
[27] Díaz-González JA, Rodríguez J, Hernández-Lizoain JL, et al.Patterns of response after preoperative treatment in gastric cancer[J]. Int J Radiat Oncol Biol Phys,2011,80(3):698-704.
[28] Pera M, Gallego R, Montagut C, et al.Phase Ⅱ trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer[J]. Ann Oncol,2012,23(3):664-670.
[29] Valenti V, Hernandez-Lizoaín JL, Beorlegui MC, et al.Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy[J]. J Surg Oncol,2011,104(2):124-129.
[30] Stahl M, Walz MK, Riera-Knorrenschild J, et al.Preope-rative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial[J]. Eur J Cancer,2017,81:183-190.
[31] Zhang ZX, Gu XZ, Yin WB, et al.Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients[J]. Int J Radiat Oncol Biol Phys,1998,42(5):929-934.
[32] Leong T, Smithers BM, Haustermans K, et al.TOPGEAR: a randomized, phase Ⅲ trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG[J]. Ann Surg Oncol,2017,24(8):2252-2258.
[33] Macdonald JS, Smalley SR, Benedetti J, et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med,2001,345(10):725-730.
[34] Lee J, Lim DH, Kim S, et al.Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol,2012,30(3):268-273.
[35] Park SH, Sohn TS, Lee J, et al.Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol,2015,33(28):3130-3136.
[36] Cheedella NK, Suzuki A, Xiao L, et al.Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort[J]. Ann Oncol,2013,24(5):1262-1266.
[37] Al-Batran SE, Hofheinz RD, Pauligk C, et al.Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial[J]. Lancet Oncol,2016,17(12):1697-1708.
[38] Al-Batran S, Homann N, Schmalenberg H, et al.Perio-perative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial[J]. J Clin Oncol,2017,35(15suppl):4004.
[39] NCI. A phase Ⅲ trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma[EB/OL].2010. [2018-12-03]. https://clinicaltrials.gov/ct2/show/NCT01196390.
[40] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature,2014,513(7517):202-209.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DAI Zhiqiang, ZHENG Jinxin, TANG Zhaoqing, ZHANG Qi, GU Yuan, SHI Zhongyi, HU Guohua, SUN Yihong. Metastatic lymph node ratio to evaluate prognosis of patients with stage Ⅱ-Ⅲ gastric cancer after radical gastrectomy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 429-434.
[2]	NIE Mingming, ZHU Zhenggang. Clinical significance of diagnostic laparoscopy on precision staging in advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 365-370.
[3]	GUO Liangqi, YAN Zhilong, ZHANG Moucheng. Laparoscopic intragastric surgery in treating of gastric submucosal tumor and early gastric cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 380-383.
[4]	LU Weihui, LIU Wei, WANG Cong, WANG Zhenglin. Effects of CXCR2 on invasion, migration and apoptosis of gastric cancer cells [J]. Journal of Surgery Concepts & Practice, 2021, 26(5): 430-436.
[5]	LIU Jingzheng, REN Zhong, HU Jianwei, QIN Wenzheng, ZHONG Yunshi, ZHOU Pinghong. Clinical effect of endoscopic full thickness resection in treatment of small gastric submucosal tumors [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 236-239.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 1-6.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 11-16.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 17-20.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 28-33.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 38-40.
[11]	YANG Zhongyin, LI Chen, LIU Wentao, SHI Min, WU Junwei, ZHENG Yanan, ZHU Zhenglun, HUA Zichen, NI Zhentian, LU Sheng, YAN Min, YAN Chao, ZHU Zhenggang. Complications of implanted subcutaneous port for intraperitoneal chemotherapy in gastric cancer patients with peritoneal metastasis and analysis of risk factors of complications [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 41-47.
[12]	LI Mei, QIU Wencai, GAO Qi, YANG Jun, JIA Zhenyi. Perioperative application of geriatric nutritional risk index in senile patients with gastrointestinal tumors [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 58-61.
[13]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 76-78.
[14]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 79-83.
[15]	. [J]. Journal of Surgery Concepts & Practice, 2020, 25(04): 341-343.